Name: 2023 American Cough Conference
Start: 08/06/2023 08:00 PM +00:00
End: 10/06/2023 08:00 PM +00:00

Learning Objectives:
1. &nbsp; &nbsp; &nbsp; Discuss patient cases and understand patient presentation of chronic cough
2. &nbsp; &nbsp; &nbsp; Review clinical guidelines
3. &nbsp; &nbsp; &nbsp; Understand potential mechanisms of disease in chronic cough

Understanding Chronic Cough: Patient Presentation and Assessment

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world &ndash; and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.&nbsp;

Merck & Co., Inc.

Bellus Health

Genetech

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational oral therapy, nalbuphine extended release (NAL ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF), refractory chronic cough, and other chronic cough indications. NAL ER is a mixed ĸ-opioid receptor agonist and &micro;-opioid receptor antagonist that works both centrally and peripherally. The ĸ and &micro; receptors are known critical mediators of cough. Trevi previously announced positive results from the Phase 2 CANAL trial for the treatment of chronic cough in IPF and is preparing to initiate the next clinical trials for this indication, along with refractory chronic cough.

Trevi Therapeutics

NeRRe is developing orvepitant, a neurokinin(NK)-1 receptor antagonist, as a first in class, once daily breakthrough treatment for cough hypersensitivity disorders. Having demonstrated proof of efficacy in patients with refractory or unexplained cough, NeRRe will now continue development in chronic cough caused by the rare and terminal lung disease idiopathic pulmonary fibrosis (IPF). A dominant feature of this severe progressive respiratory disease in a high proportion of patients is an uncontrolled and persistent cough which is disabling for these terminally ill patients. The cough is often refractory to medical therapy and there are no approved treatments for it. Idiopathic pulmonary fibrosis has been designated and orphan disease in both Europe and the USA.

NeRRe Therapeutics

Reckitt exists to protect, heal and nurture in the relentless pursuit of a cleaner, healthier world. We believe that access to the highest-quality hygiene, wellness and nourishment is a right, not a privilege.
Reckitt is the company behind some of the world&rsquo;s most recognizable and trusted consumer brands in hygiene, health and nutrition, including Air Wick, Biofreeze, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, K-Y, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, , Veet, Woolite and more.
In the U.S., Reckitt markets Mucinex and Delsym as part of its over-the-counter medicine portfolio. Mucinex is the number one recommended brand in the adult cough/cold category in the U.S. among the universe of physicians. *
&nbsp;
*Source: IQVIA, ProVoice physician survey, 52 weeks ending December 2022.

Reckitt

Our Mission is to improve patient lives by designing and manaufacturing market leading product and services.
We have decades of expeerience in the manufacture and supply of respiratory diagnostic devices trusted by both medical professionals and patients alike.
Our intention is to have a real impact in the effective management of respiratory diseases. We provide a wide varitety of precise, intuitive devices for respiratory care including spirometers, lung and asthma monitors, COPD screeners, medical workstations as well as software consumables.

Vitalograph

Strados Labs, Inc

Soundable Health is a digital health startup that provides innovative health monitoring solutions using everyday sounds. With its unsurpassed AI sound analytics, Soundable Health is leading the discovery and development of new digital audible biomarkers that can be detected using smartphones. The new audible biomarkers pioneered by Soundable Health range across various medical fields, especially with underserved chronic symptoms including respiratory cough symptoms (Coughy&reg;) and benign prostatic hyperplasia (BPH) in urology (proudP&reg;).&nbsp;

Coughy by Soundable

Algernon Pharmaceuticals is a clinical-stage, Canadian drug development and repurposing company investigating drugs and naturally occurring compounds for unmet global medical needs.
Algernon&rsquo;s drug repurposing model provides a cost-effective and capital efficient method for the discovery of new therapeutic uses for drugs that are off patent and have a well-known safety history, but have never been marketed in the U.S. or Europe. Repurposing existing, safe, small molecules to treat different disease applications requires lower capital investment, has a reduced risk of failure due to toxicity or safety issues, and usually features shorter development periods because the compounds can be moved into clinical trials more quickly than new chemical entities.
Algernon Pharmaceuticals candidate NP-120, also known as Ifenprodil, is the drug we are advancing in our chronic cough and idiopathic pulmonary fibrosis (IPF) research program. NP-120 is a small molecule approved in Japan and South Korea to treat vertigo caused by ischemic stroke. Recent preclinical in vivo animal studies show that NP-120 compared favorably to the world&rsquo;s leading two treatments for IPF (Nintedanib and Pirfenidone), reducing fibrosis by 56 percent.
We have recently concluded a Phase 2a study of Ifenprodil in patients with IPF and chronic cough. The trial met its co-primary endpoint with patients receiving Ifenprodil experiencing no worsening of their lung function, and significant improvements were seen in the frequency of their IPF-associated cough as well.

Algernon Pharmaceuticals

Plesae see individual sessions for video, information on speakers and to view supplimental files.&nbsp;

All Day Live Stream

8:30&nbsp; &nbsp; &nbsp;Welcome Day 2 &ndash; Peter Dicpinigaitis
&nbsp;
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Session 3 &ndash;&nbsp; Chronic Cough Evaluation and Management &ndash; Chair: Jacky Smith
8:35&nbsp; &nbsp; &nbsp;Cough counting technology update. &ndash; Peter Small
9:00&nbsp; &nbsp; &nbsp;Clinical cough monitoring: past, present, future. &ndash; &nbsp;Frank Keane&nbsp;
9:25&nbsp; &nbsp; &nbsp;The science and place of Cough-omics in chronic cough. &ndash; K. Fan Chung
9:50&nbsp; &nbsp; &nbsp;The role of the speech-language pathologist in the management of refractory chronic cough. &ndash; Laurie Slovarp
Note: Questions submitted on the app and platform will be provided to speakers at the end of the conference. Those that are answered will be emailed to all participants.&nbsp;

Peter Dicpinigaitis

Jacky Smith

Peter Small

Frank Keane

Fan Chung

Laurie Slovarp

Session 3- Chronic Cough Evaluation and Management

Antitussive Drug Development Programs Updates&nbsp;
Chairs: K. Fan Chung, Surinder Birring
&nbsp;
10:35 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Gefapixant &ndash; Carmen La Rosa
11:00 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Camlipixant&nbsp;BLU-5937 &ndash; Cathy Bonuccelli
11:25 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Development Plans for Nalbuphine ER in Cough &ndash; Thomas Sciascia
11:50 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Orvepitant &ndash; Steve Pawsey
12:15 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;NTX-1175 &ndash; Jim Ellis
Note: Questions submitted on the app and platform will be provided to speakers at the end of the conference. Those that are answered will be emailed to all participants.&nbsp;

Surinder Birring

Carmen La Rosa

Catherine Bonuccelli

Thomas Sciascia

Steve Pawsey

James Ellis

Antitussive Drug Development Programs- Updates - Session 1

Chairs: Lorcan McGarvey, Peter Dicpinigaitis
13:40 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; AX-8 (TRPM-8 agonist) &ndash; Michael Kitt
14:05 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Ifenprodil &ndash; Christopher Bryan
14:30 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; A role for azithromycin in chronic cough? What is the evidence? &ndash; Alyn Morice
14:55 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;The therapeutic landscape in chronic cough. &ndash; Jacky Smith &nbsp;
&nbsp;
15:20 - 15:30&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Conference Conclusion &ndash; Peter Dicpinigaitis&nbsp; &nbsp;
Note: Questions submitted on the app and platform will be provided to speakers at the end of the conference. Those that are answered will be emailed to all participants.&nbsp;

Program

Speakers22 Speakers

Peter Dicpinigaitis

Surinder Birring

Catherine Bonuccelli

Christopher Bryan

Brendan Canning

Fan Chung

Matthew Drake

David Edwards

James Ellis

Nathaniel Katz

Frank Keane

Michael Kitt

Carmen La Rosa

Stuart Mazzone

Lorcan McGarvey

Alyn Morice

Steven Nathan

Steve Pawsey

Thomas Sciascia

Laurie Slovarp

Peter Small

Jacky Smith

Sponsors12 Sponsors

Understanding Chronic Cough: Patient Presentation and Assessment

Merck & Co., Inc.

Bellus Health

Genetech

Trevi Therapeutics

NeRRe Therapeutics

P&G

Reckitt

Vitalograph

Strados Labs, Inc

Coughy by Soundable

Algernon Pharmaceuticals

Program

Speakers.css-1umfhuz{margin:0;font-size:1.4rem;font-weight:500;line-height:1.5;color:#d3d1de;font-family:'Poppins',sans-serif;margin-left:0.8rem;}22 Speakers

Peter Dicpinigaitis

Surinder Birring

Catherine Bonuccelli

Christopher Bryan

Brendan Canning

Fan Chung

Matthew Drake

David Edwards

James Ellis

Nathaniel Katz

Frank Keane

Michael Kitt

Carmen La Rosa

Stuart Mazzone

Lorcan McGarvey

Alyn Morice

Steven Nathan

Steve Pawsey

Thomas Sciascia

Laurie Slovarp

Peter Small

Jacky Smith

Sponsors.css-5jjj24{margin:0;font-size:1.4rem;font-weight:500;line-height:1.5;color:#d3d1de;font-family:'Poppins',sans-serif;color:#ffffff;margin-left:0.8rem;font-weight:400;}12 Sponsors

Understanding Chronic Cough: Patient Presentation and Assessment

Merck & Co., Inc.

Bellus Health

Genetech

Trevi Therapeutics

NeRRe Therapeutics

P&G

Reckitt

Vitalograph

Strados Labs, Inc

Coughy by Soundable

Algernon Pharmaceuticals

Speakers22 Speakers

Sponsors12 Sponsors